Immunotherapies influence the influenza vaccination response in multiple sclerosis patients: an explorative study

2014 ◽  
Vol 20 (8) ◽  
pp. 1074-1080 ◽  
Author(s):  
Henning K Olberg ◽  
Rebecca J Cox ◽  
Jane K Nostbakken ◽  
Jan H Aarseth ◽  
Christian A Vedeler ◽  
...  
Keyword(s):  
Influenza Vaccination ◽  
Seasonal Influenza ◽  
Interferon Beta ◽  
Swine Flu ◽  
Serological Response ◽  
Pandemic H1n1 ◽  
Immunomodulatory Treatment ◽  
Seasonal Influenza Vaccination ◽  
Explorative Study ◽  
Multiple Sclerosis Patients

Background: The immunogenicity of influenza vaccines in MS patients undergoing immunomodulatory treatment is not well studied. Objectives: This explorative study investigated the influence of immunomodulatory treatment on MS patients receiving pandemic H1N1 (swine flu) vaccination in 2009 and seasonal influenza vaccination in 2010. Methods: We investigated the immune response to pandemic H1N1 vaccination among 113 MS patients and 216 controls during the pandemic of 2009. We also investigated the serological response to seasonal influenza vaccination (2010 – 2011 season) among 49 vaccinated and 62 non-vaccinated MS patients, versus 73 controls. We evaluated these vaccine responses by haemagglutination inhibition assay. Results: MS patients receiving immunomodulatory treatment had reduced protection (27.4%), compared to controls (43.5%) ( p = 0.006), after pandemic H1N1 vaccination (2009). The rates of protection were not influenced by interferon beta treatment (44.4% protected), but were reduced among patients receiving glatiramer acetate (21.6%), natalizumab (23.5%), and mitoxantrone (0.0%). A similar pattern emerged after MS patients received a seasonal influenza vaccination in 2010. Conclusions: These findings suggest that MS patients receiving immunomodulatory therapies other than interferon beta should be considered for a vaccine response analysis and perhaps be offered a second dose of the vaccine, in cases of insufficient protection.

Seasonal influenza vaccination predicts pandemic H1N1 vaccination uptake among healthcare workers in three countries

Vaccine ◽  
2011 ◽  
Vol 29 (43) ◽  
pp. 7364-7369 ◽  
Author(s):  
Josette S.Y. Chor ◽  
Surinder K. Pada ◽  
Iain Stephenson ◽  
William B. Goggins ◽  
Paul A. Tambyah ◽  
...  
Keyword(s):  
Influenza Vaccination ◽  
Healthcare Workers ◽  
Seasonal Influenza ◽  
Pandemic H1n1 ◽  
Seasonal Influenza Vaccination ◽  
Vaccination Uptake

scholarly journals Annual influenza vaccination of patients with cardiovascular diseases and changes in hemagglutinin antibody titers: 3-year follow-up data

2020 ◽  
Vol 25 (2) ◽  
pp. 88-101
Author(s):  
Elena V. Platonova ◽  
Alexandr D. Deev ◽  
Vladimir M. Gorbunov ◽  
Olga A. Nazarova ◽  
Olga A. Belova ◽  
...  
Keyword(s):  
Cardiovascular Diseases ◽  
Influenza Vaccination ◽  
Vaccination Coverage ◽  
Seasonal Influenza ◽  
Influenza Infection ◽  
Logarithmic Scale ◽  
Serological Response ◽  
Seasonal Influenza Vaccination ◽  
Antibody Titers

BACKGROUND: Seasonal influenza vaccination is recommended for patients with cardiovascular diseases. Low vaccination coverage among these patients is due to insufficient knowledge about vaccine efficiency and its regular annual use. This work aimed to study the repeated 6-month changes in hemagglutinin antibody titers (AT) for 3 years in patients with cardiac pathology in a comparative study of influenza preventive vaccination. MATERIALS AND METHODS: Analysis of ATs obtained based on the hemagglutination-inhibition test (HAI) was performed in 235 of 817 participants in a prospective follow-up. Blood sampling was performed at baseline, before the vaccination, and 6 months after, and at the same term in unvaccinated patients in the 20122013 and 20142015 seasons, respectively. The seropositive and seronegative responses to vaccination or acute respiratory or influenza infection were used, according to the reference values of seroconversion and seroprotection and the fact of seroconversion. Multiple regression analysis with a logarithmic scale was used to assess the vaccine effectiveness indices. RESULTS: With vaccination coverage of at least 40% against seasonal influenza within 3 years, the trends of a decrease in seropositive and an increase in seronegative responses in the vaccination group and its reverse nature in the comparison group were determined by traditional analysis. Using logarithmic calculation, an increase in HAI AT seroconversion was revealed over a 3-year follow-up period. It was characterized by a homogeneous serological response at annual vaccination and heterogeneous with a higher serological response in cases without vaccination (p = 0.002 for H1N1 and p = 0.005 for H3N2, respectively). This trend can be determined by a higher and more stable prevaccination level of HAI AT than the same residual level of AT among unvaccinated patients. CONCLUSION: During long-term cardiac studies, the logarithmic calculation in interpreting the results of HAI AT overcomes the limitations of the traditional analysis of assessing the efficiency of the annual influenza vaccine. Further serological programs are required to better understand the role of routine seasonal influenza vaccination in preventing morbidity and mortality of patients with cardiovascular diseases.

No effect of 2008/09 seasonal influenza vaccination on the risk of pandemic H1N1 2009 influenza infection in England

Vaccine ◽  
2011 ◽  
Vol 29 (14) ◽  
pp. 2613-2618 ◽  
Author(s):  
Richard Pebody ◽  
Nick Andrews ◽  
Pauline Waight ◽  
Rashmi Malkani ◽  
Christine McCartney ◽  
...  
Keyword(s):  
Influenza Vaccination ◽  
Seasonal Influenza ◽  
Influenza Infection ◽  
Pandemic H1n1 ◽  
Seasonal Influenza Vaccination ◽  
Pandemic H1n1 2009

scholarly journals Impact of national influenza vaccination strategy in severe influenza outcomes among the high-risk Portuguese population

2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Ausenda Machado ◽  
Irina Kislaya ◽  
Amparo Larrauri ◽  
Carlos Matias Dias ◽  
Baltazar Nunes
Keyword(s):  
High Risk ◽  
Influenza Vaccination ◽  
Seasonal Influenza ◽  
Vaccine Coverage ◽  
Vaccination Strategy ◽  
High Risk Population ◽  
Risk Population ◽  
Seasonal Influenza Vaccination ◽  
Severe Influenza ◽  
The Impact

Abstract Background All aged individuals with a chronic condition and those with 65 and more years are at increased risk of severe influenza post-infection complications. There is limited research on cases averted by the yearly vaccination programs in high-risk individuals. The objective was to estimate the impact of trivalent seasonal influenza vaccination on averted hospitalizations and death among the high-risk population in Portugal. Methods The impact of trivalent seasonal influenza vaccination was estimated using vaccine coverage, vaccine effectiveness and the number of influenza-related hospitalizations and deaths. The number of averted events (NAE), prevented fraction (PF) and number needed to vaccinate (NVN) were estimated for seasons 2014/15 to 2016/17. Results The vaccination strategy averted on average approximately 1833 hospitalizations and 383 deaths per season. Highest NAE was observed in the ≥65 years population (85% of hospitalizations and 95% deaths) and in the 2016/17 season (1957 hospitalizations and 439 deaths). On average, seasonal vaccination prevented 21% of hospitalizations in the population aged 65 and more, and 18.5% in the population with chronic conditions. The vaccination also prevented 29% and 19.5% of deaths in each group of the high-risk population. It would be needed to vaccinate 3360 high-risk individuals, to prevent one hospitalization and 60,471 high-risk individuals to prevent one death. Conclusion The yearly influenza vaccination campaigns had a sustained positive benefit for the high-risk population, reducing hospitalizations and deaths. These results can support public health plans toward increased vaccine coverage in high-risk groups.

Sign in / Sign up

Export Citation Format

Share Document